1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 製品タイプ別スニペット
3.2. モダリティ別スニペット
3.3. 透析タイプ別スニペット
3.4. 患者年齢層別スニペット
3.5. 技術別スニペット
3.6. エンドユーザー別スニペット
3.7. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 慢性腎臓病の増加
4.1.2. 阻害要因
4.1.3. 処置に伴う合併症
4.1.4. 認識不足
4.1.5. 機会
4.1.6. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. アンメット・ニーズ
5.6. PESTEL分析
5.7. 特許分析
5.8. SWOT分析
6. 製品タイプ別
6.1. 製品紹介
6.1.1. 製品タイプ別市場規模分析および前年比成長率分析(%)
6.1.2. 市場魅力度指数（製品タイプ別
6.2. 血液透析装置
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. ダイアライザー
6.4. 血液ラインシステムおよびチューブセット
6.5. 濃縮液および溶液
6.6. バスキュラーアクセスデバイス
6.7. 血液透析フィルターおよびカートリッジ
7. モダリティ別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）, モダリティ別
7.1.2. 市場魅力度指数（モダリティ別
7.2. 従来型血液透析（HD）*市場
7.2.1. 導入
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 夜間血液透析
7.4. 短時間血液透析
7.5. 在宅血液透析（HHD）
8. 透析タイプ別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析（%）、透析タイプ別
8.1.2. 市場魅力度指数（透析タイプ別
8.2. センター内透析
8.2.1. 導入
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 在宅透析
9. 患者年齢層別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析（%）、患者年齢層別
9.2. 市場魅力度指数（患者年齢層別
9.3. 小児患者*市場
9.3.1. はじめに
9.3.2. 市場規模分析と前年比成長率分析(%)
9.4. 成人患者
9.5. 老人患者
10. 技術別
10.1. はじめに
10.1.1. 市場規模分析および前年比成長率分析（%）, 技術別
10.1.2. 市場魅力度指数、技術別
10.2. 高性能血液透析（HPHD）*市場
10.2.1. 導入
10.2.2. 市場規模分析と前年比成長率分析(%)
10.3. 拡張血液透析（HDx）
10.4. 血液透析濾過（HDF）
10.5. 従来の血液透析
11. エンドユーザー別
11.1. はじめに
11.1.1. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
11.1.2. 市場魅力度指数、エンドユーザー別
11.2. 病院*市場
11.2.1. はじめに
11.2.2. 市場規模分析と前年比成長率分析(%)
11.3. 透析センター
11.4. 在宅医療施設
11.5. 専門クリニック
12. 地域別
12.1. はじめに
12.1.1. 地域別市場規模分析および前年比成長率分析(%)
12.1.2. 市場魅力度指数、地域別
12.2. 北米
12.2.1. 序論
12.2.2. 主な地域別ダイナミクス
12.2.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
12.2.4. 市場規模分析およびYoY成長率分析（%）、モダリティ別
12.2.5. 市場規模分析および前年比成長率分析（%）, 透析タイプ別
12.2.6. 市場規模分析および前年比成長率分析（%）, 患者年齢層別
12.2.7. 市場規模分析および前年比成長率分析（%）, 技術別
12.2.8. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
12.2.9. 市場規模分析および前年比成長率分析(%)、国別
12.2.9.1. 米国
12.2.9.2. カナダ
12.2.9.3. メキシコ
12.3. ヨーロッパ
12.3.1. はじめに
12.3.2. 主な地域別ダイナミクス
12.3.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
12.3.4. 市場規模分析およびYoY成長率分析(%)、モダリティ別
12.3.5. 市場規模分析および前年比成長率分析(%)、透析タイプ別
12.3.6. 市場規模分析および前年比成長率分析（%）：患者年齢層別
12.3.7. 市場規模分析および前年比成長率分析(%)、技術別
12.3.8. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
12.3.9. 市場規模分析および前年比成長率分析(%)、国別
12.3.9.1. ドイツ
12.3.9.2. イギリス
12.3.9.3. フランス
12.3.9.4. イタリア
12.3.9.5. スペイン
12.3.9.6. その他のヨーロッパ
12.4. 南米
12.4.1. はじめに
12.4.2. 主な地域別ダイナミクス
12.4.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
12.4.4. 市場規模分析およびYoY成長率分析（%）、モダリティ別
12.4.5. 市場規模分析および前年比成長率分析(%)、透析タイプ別
12.4.6. 市場規模分析および前年比成長率分析（%）：患者年齢層別
12.4.7. 市場規模分析および前年比成長率分析(%)、技術別
12.4.8. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
12.4.9. 市場規模分析および前年比成長率分析(%)、国別
12.4.9.1. ブラジル
12.4.9.2. アルゼンチン
12.4.9.3. その他の南米地域
12.5. アジア太平洋
12.5.1. はじめに
12.5.2. 主な地域別ダイナミクス
12.5.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
12.5.4. 市場規模分析および前年比成長率分析（%）、モダリティ別
12.5.5. 市場規模分析および前年比成長率分析（%）, 透析タイプ別
12.5.6. 市場規模分析および前年比成長率分析（%）：患者年齢層別
12.5.7. 市場規模分析および前年比成長率分析（%）, 技術別
12.5.8. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
12.5.9. 市場規模分析および前年比成長率分析(%)、国別
12.5.9.1. 中国
12.5.9.2. インド
12.5.9.3. 日本
12.5.9.4. 韓国
12.5.9.5. その他のアジア太平洋地域
12.6. 中東・アフリカ
12.6.1. 序論
12.6.2. 主な地域別ダイナミクス
12.6.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
12.6.4. 市場規模分析およびYoY成長率分析(%)、モダリティ別
12.6.5. 市場規模分析および前年比成長率分析(%)、透析タイプ別
12.6.6. 市場規模分析および前年比成長率分析（%）：患者年齢層別
12.6.7. 市場規模分析および前年比成長率分析(%)、技術別
12.6.8. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
13. 競争環境
13.1. 競争シナリオ
13.2. 市場ポジショニング／シェア分析
13.3. M&A分析
14. 企業プロフィール
14.1. Fresenius Medical Care AG & Co. KGaA*
14.1.1. 会社概要
14.1.2. 製品ポートフォリオと内容
14.1.3. 財務概要
14.1.4. 主な展開
14.2. Baxter
14.3. Nikkiso Co., Ltd.
14.4. B. Braun Melsungen AG
14.5. Asahi Kasei Corporation
14.6. Nipro Corporation
14.7. Rockwell Medical, Inc.
14.8. Medtronic plc
14.9. Dialife SA
14.10. AWAK Technologies
リストは網羅的ではありません
15. 付録
15.1. 会社概要とサービス
15.2. お問い合わせ

Overview
The global hemodialysis therapy market reached US$ 13.03 billion in 2023 and is expected to reach US$ 19.81 billion by 2031, growing at a CAGR of 5% during the forecast period 2024-2031.

Hemodialysis is a treatment that replaces the work of one’s kidneys to clear wastes and extra fluid from the blood. This is done using a special filter called a dialyzer or artificial kidney. The blood travels through plastic tubing to the dialyzer, where it is cleaned and then returned to the patient.
The dialysis machine pumps the blood through the dialysis system and controls the treatment time, temperature, fluid removal, and pressure.
The increasing prevalence of chronic kidney diseases across the globe is expected to drive the demand for hemodialysis therapy. For instance, according to the National Kidney Foundation, chronic kidney disease (CKD) affects around 10% of the global population. Between 5.3 and 10.5 million people need dialysis or transplantation.

Market Dynamics: Drivers
Increasing prevalence of chronic kidney disorders
The rising prevalence of chronic kidney disorders propels the market growth. As a result of the increasing prevalence of chronic diseases, the inability of the kidneys of people suffering from chronic kidney disease to purify the toxins from blood is increasing day by day and as a result of that, the demand for hemodialysis therapy which helps the kidney to purify the toxins from blood in an artificial method is increasing.
For instance, according to the National Institute of Health, chronic kidney disease is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals. Chronic kidney disease is more prevalent in older individuals, women, racial minorities, and in people experiencing diabetes mellitus and hypertension. Chronic kidney disease represents an especially large burden in low- and middle-income countries, which are least equipped to deal with its consequences.
Moreover, according to the National Kidney Foundation, over 2 million people worldwide currently receive treatment with dialysis or a kidney transplant to stay alive, yet this number may only represent 10% of people who actually need treatment to live. It is estimated that the number of cases of kidney failure will increase disproportionately in developing countries, such as China and India, where the number of elderly people is increasing.
Of the 2 million people who receive treatment for kidney failure, the majority are treated in only five countries – the United States, Japan, Germany, Brazil, and Italy. These five countries represent only 12% of the world's population. Only 20% are treated in about 100 developing countries that make up over 50% of the world population. As a result of the expanding frequency of chronic kidney diseases has a substantial impact on the hemodialysis therapy industry, boosting demand for treatments, driving up economic expenses, and prompting technological developments.

Restraints
Factors such as complications linked with the procedure and lack of awareness among people are expected to hamper the market. According to statistics from the National Kidney Foundation, chronic kidney disease affects 10% of the global population and is the 12th leading cause of death. Every year, millions of people die because they do not have access to cost-effective therapy.
For more details on this report - Request for Sample

Segment Analysis
The global hemodialysis therapy market is segmented based on product type, modality, dialysis type, patient age group, technology, end-user, and region.

The segment hemodialysis machines accounted for approximately XX% of the global hemodialysis therapy market share
The hemodialysis machines segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements, recent launches, and raising funds for private manufacturers for device development would drive this market.
A hemodialysis machine is medical equipment that acts as an artificial kidney, assisting individuals whose kidneys are unable to execute their natural filtering activities owing to chronic renal disease or acute kidney injury. The machine works by eliminating waste materials and excess fluids from the blood, which prevents the accumulation of toxins in the body. These machines are highly distinctive, and they use a sophisticated system that includes a blood circuit, a dialyzer, and a dialysate circuit.
The dialyzer is noteworthy for its semi-permeable membrane, which enables the selective removal of poisons and excess electrolytes while preserving bigger molecules such as proteins and blood cells. New hemodialysis machines are being introduced into the market by several players which could contribute to the segment’s expansion. For instance, in March 2024, Bussum, the Netherlands-based Nextkidney, a medtech company, announced that it has developed the world’s first portable hemodialysis device, Neokidney.
According to the Dutch company, Neokidney is in the final development phase and is expected to launch in the Netherlands by 2024. Moreover, in August 2024, Synopex, a medical device manufacturer, obtained marketing authorization from the Ministry of Food and Drug Safety (MFDS) for the nation's first independently developed continuous renal replacement therapy (CRRT) device for critical care patients. Thus, the hemodialysis machines segment is expected to hold the major portion of the hemodialysis therapy market share with the increasing number of launches and technological innovations of new machines and their effectiveness in finding antibodies over other types of tests.

Geographical Analysis
North America accounted for approximately XX% of the global hemodialysis therapy market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of chronic kidney diseases, technological advancements, and increase in fund allotment in this region, help to propel the market.
The prevalence of kidney diseases in this region is increasing at an alarming rate which increases and drives the demand for the hemodialysis therapy market. For instance, according to the American Kidney Fund, over 35.5 million Americans suffer from renal disease. An estimated 808,000 Americans suffer from renal failure. More than 557,000 Americans are undergoing dialysis. Kidney disease is increasing at an alarming rate. It presently affects more than one in every seven (14%) American adults, with persons of color being more likely to develop renal failure. In 2021, over 135,000 Americans received a new diagnosis of renal failure. Nine out of ten patients with renal disease are uninformed of their condition, and one-third of those with significantly diminished kidney function are also unaware.
The increase in the allotment of funds by the government and private organizations for research and technological development activities. Due to fund allotment, manufacturers research and develop advanced technology and machinery which drives the market in this region. AWAK Technologies secured almost $20 million in Series B funding for their wearable dialysis device's critical trial in the United States. AWAK PD, an ultra-portable peritoneal dialysis (PD) equipment, enables kidney disease patients to get dialysis at home or on the go. The revenues will be used by the company to fund a number of critical activities, including the completion of an ongoing human pre-pivotal clinical research with Singapore General Hospital. The money will also assist the business enhance the ultraportable PD device for the final pivotal trial in the United States, which is expected to begin in 2025.

Market Segmentation
By Product Type
• Hemodialysis Machines
• Dialyzers
o High-Flux Dialyzers
o Low-Flux Dialyzers
• Bloodline Systems and Tubing Sets
• Concentrates and Solutions
o Acid Concentrates
o Bicarbonate Concentrates
• Vascular Access Devices
o Dialysis Catheters
o AV Fistulas
o Grafts
• Hemodialysis Filters and Cartridges
By Modality
• Conventional Hemodialysis (HD)
• Nocturnal Hemodialysis
• Short Daily Hemodialysis
• Home Hemodialysis (HHD)
By Dialysis Type
• In-Center Dialysis
• Home Dialysis
By Patient Age Group
• Pediatric Patients
• Adult Patients
• Geriatric Patients
By Technology
• High-Performance Hemodialysis (HPHD)
• Expanded Hemodialysis (HDx)
• Hemodiafiltration (HDF)
• Conventional Hemodialysis
By End-User
• Hospitals
• Dialysis Centers
• Homecare Settings
• Specialty Clinics
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape
The major global players in the global hemodialysis therapy market include Fresenius Medical Care AG & Co. KGaA, Baxter, Nikkiso Co., Ltd., B. Braun Melsungen AG, Asahi Kasei Corporation
Nipro Corporation, Rockwell Medical, Inc., Medtronic plc, Dialife SA, AWAK Technologies among others.

Key Developments
 On May 2024, Baxter International Inc., a global innovator in kidney care and vital organ support, today announced new data demonstrating that expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (HF HD).
 In April 2023, AWAK Technologies, a Singapore-based medical technology company, recently received FDA Breakthrough Device designation for their wearable and portable dialysis device. The AWAK Peritoneal Dialysis device, or AWAK PD, uses AWAK’s patented sorbent technology and offers a convenient means of dialysis for renal disease patients.

Why Purchase the Report?
• To visualize the global hemodialysis therapy
Market Segmentation based on product type, modality, dialysis type, patient age group, technology, end-user, and region., as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global hemodialysis therapy market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global hemodialysis therapy market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Modality
3.3. Snippet by Dialysis Type
3.4. Snippet by Patient Age Group
3.5. Snippet by Technology
3.6. Snippet by End-User
3.7. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Chronic Kidney Diseases
4.1.2. Restraints
4.1.3. Complications Linked With Procedure
4.1.4. Lack of Awareness
4.1.5. Opportunity
4.1.6. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Hemodialysis Machines*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Dialyzers
6.4. Bloodline Systems and Tubing Sets
6.5. Concentrates and Solutions
6.6. Vascular Access Devices
6.7. Hemodialysis Filters and Cartridges
7. By Modality
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
7.1.2. Market Attractiveness Index, By Modality
7.2. Conventional Hemodialysis (HD)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Nocturnal Hemodialysis
7.4. Short Daily Hemodialysis
7.5. Home Hemodialysis (HHD)
8. By Dialysis Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dialysis Type
8.1.2. Market Attractiveness Index, By Dialysis Type
8.2. In-Center Dialysis*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Home Dialysis
9. By Patient Age Group
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age Group
9.2. Market Attractiveness Index, By Patient Age Group
9.3. Pediatric Patients*
9.3.1. Introduction
9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.4. Adult Patients
9.5. Geriatric Patients
10. By Technology
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.1.2. Market Attractiveness Index, By Technology
10.2. High-Performance Hemodialysis (HPHD)*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Expanded Hemodialysis (HDx)
10.4. Hemodiafiltration (HDF)
10.5. Conventional Hemodialysis
11. By End-User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Dialysis Centers
11.4. Homecare Settings
11.5. Specialty Clinics
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dialysis Type
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age Group
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.9.1. U.S.
12.2.9.2. Canada
12.2.9.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dialysis Type
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age Group
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.9.1. Germany
12.3.9.2. UK
12.3.9.3. France
12.3.9.4. Italy
12.3.9.5. Spain
12.3.9.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dialysis Type
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age Group
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.9.1. Brazil
12.4.9.2. Argentina
12.4.9.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dialysis Type
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age Group
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.9.1. China
12.5.9.2. India
12.5.9.3. Japan
12.5.9.4. South Korea
12.5.9.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dialysis Type
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age Group
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
12.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Fresenius Medical Care AG & Co. KGaA*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Baxter
14.3. Nikkiso Co., Ltd.
14.4. B. Braun Melsungen AG
14.5. Asahi Kasei Corporation
14.6. Nipro Corporation
14.7. Rockwell Medical, Inc.
14.8. Medtronic plc
14.9. Dialife SA
14.10. AWAK Technologies
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

※参考情報 血液透析療法は、腎臓の機能が低下した患者に対して行われる治療法です。この療法は、体内から余分な水分や老廃物、電解質を除去し、血液の成分を正常に保つことを目的としています。腎不全患者にとって、血液透析は命を維持するための重要な治療手段となります。 血液透析にはいくつかの種類があります。最も一般的な形式は、施設で行う「成人血液透析」です。患者は一定の間隔で透析センターに訪れ、大型の透析装置を使用して治療を受けます。また、患者自身が自宅で行う「在宅血液透析」というスタイルもあります。これは、患者にあらかじめ教育を受け、必要な機器を整備することで可能になります。更に定期的に医療者によるフォローアップが行われるため、患者は自宅での生活を継続しつつ、透析治療を受けられます。 血液透析の主な用途は、慢性腎不全や急性腎不全の患者に対する治療です。特に、慢性腎不全の患者は、腎機能が持続的に低下しているため、定期的な透析が必須となります。また、急性腎不全の場合でも、一時的な血液浄化が必要になることがあります。そのため、透析のスケジュールや実施頻度は患者の病状により異なりますが、通常は週に3回、1回のセッションが約4から5時間にわたるケースが多いです。 血液透析には、透析膜を通して血液を浄化する「透析法」が基本的なメカニズムです。血液が透析装置に引き込まれ、フィルターの役割を果たす膜（透析膜）を通ることで、不要な物質や余分な水分が除去されます。この際、膜の両側に置かれた洗浄液（透析液）が、血液と不純物の拡散を促進します。透析液には、体内に必要な成分や電解質が含まれており、適切なバランスを保ちながら体内環境を整えます。 関連技術としては、血液透析の精度を上げるために様々な進化が見られます。例えば、低透析膜透過性や新しい洗浄液の開発が進められています。また、モニタリング技術の向上により、患者の血液の成分や透析時間をリアルタイムで監視することが可能になっています。これにより、個々の患者に合わせた最適な治療の提供が実現しています。 さらに、近年は人工知能や機械学習を用いたデータ分析が進化し、血液透析の管理や予測に役立てられるようになっています。患者の個別のデータをもとに、より効果的な治療計画を策定することが期待されています。 血液透析療法は、腎臓の機能を代替する重要な手段であり、多くの患者にとって生活の質を大きく向上させる役割を果たしています。透析によって体内の有害物質を除去することで、日常生活を維持しやすくなります。また、透析治療を受けることで腎機能の進行を遅らせたり、合併症を防ぐことが可能になります。しかし、透析患者にとっては、食事制限や定期的な通院などの生活上の制約があることも事実です。そのため、患者と医療チームとの連携が重要であり、治療の質を高めるための努力が求められます。 血液透析は、腎不全の管理において欠かせない技術であり、今後もさらなる進化が期待されます。これにより、患者の生活の質がさらに向上し、より多くの人々が健康で快適な生活を送れるようになることが望まれます。

❖ 世界の血液透析療法市場に関するよくある質問(FAQ) ❖

・血液透析療法の世界市場規模は？
→DataM Intelligence社は2023年の血液透析療法の世界市場規模を130億3,000万米ドルと推定しています。

・血液透析療法の世界市場予測は？
→DataM Intelligence社は2031年の血液透析療法の世界市場規模を198億1,000万米ドルと予測しています。

・血液透析療法市場の成長率は？
→DataM Intelligence社は血液透析療法の世界市場が2024年～2031年に年平均5.0%成長すると予測しています。

・世界の血液透析療法市場における主要企業は？
→DataM Intelligence社は「Fresenius Medical Care AG & Co. KGaA, Baxter, Nikkiso Co., Ltd., B. Braun Melsungen AG, Asahi Kasei Corporation
Nipro Corporation, Rockwell Medical, Inc., Medtronic plc, Dialife SA, AWAK Technologiesなど ...」をグローバル血液透析療法市場の主要企業として認識しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。